Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
At present, immune checkpoint inhibitors, such as pembrolizumab, are widely used in the therapy of advanced non-resectable melanoma, as they induce more durable responses than other available treatments. However, the overall response rate does not exceed 50% and, considering the high costs and low life expectancy of nonresponding patients, there is...
Alternative Titles
Full title
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b755296c408f4d62bce273d786ad6e82
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b755296c408f4d62bce273d786ad6e82
Other Identifiers
ISSN
1479-5876
E-ISSN
1479-5876
DOI
10.1186/s12967-019-2081-2
